PTH suppression by calcitriol does not predict off‐target actions in experimental CKD

Vitamin D receptor agonist (VDRA) therapy for PTH suppression is a mainstay for patients with severe CKD. Calcitriol (1,25‐(OH)(2)D(3)) is a former first‐line VDRA in CKD treatment. However, a consequence of its use in CKD is accelerated vascular calcification (VC). An experimental CKD model was use...

Descripción completa

Detalles Bibliográficos
Autores principales: Svajger, Bruno A., Pruss, Cynthia M., Laverty, Kimberly J., Zelt, Jason G. E., Jones, Glenville, Kaufmann, Martin, Petkovich, Martin, Holden, Rachel M., Adams, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283992/
https://www.ncbi.nlm.nih.gov/pubmed/32519465
http://dx.doi.org/10.1002/prp2.605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283992/
https://www.ncbi.nlm.nih.gov/pubmed/32519465
http://dx.doi.org/10.1002/prp2.605

Ejemplares similares